A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
暂无分享,去创建一个
W. Novotny | R. Preston | T. Marbury | Y. Ou | S. Sahasranaman | Zhiyu Tang | M. Tawashi | Ta‐Kai Li
[1] W. Novotny,et al. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects , 2019, Cancer Chemotherapy and Pharmacology.
[2] R. Elstrom,et al. Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. , 2019, Blood.
[3] M. Dimopoulos,et al. PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111) , 2019 .
[4] W. Humphreys,et al. Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study , 2018, Drug Metabolism and Disposition.
[5] William Smith,et al. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment* , 2017, Leukemia & lymphoma.
[7] J. Bircher,et al. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. , 1989, Scandinavian journal of gastroenterology.
[8] M. Rothschild,et al. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. , 1969, The Journal of clinical investigation.